About this trial
Migraine is a primary headache disorder characterized by recurrent episodes of moderate to severe pain, frequently accompanied by nausea, photophobia, and phonophobia. It ranks as the third most prevalent medical condition globally and is recognized by the World Health Organization (WHO) as one of the top ten causes of disability worldwide. Migraine presents substantial public health concerns due to its considerable socioeconomic burden and its detrimental impact on individuals' quality of life. Although pharmacological treatments are widely available, their effectiveness is often limited, with many patients experiencing inadequate symptom relief or adverse side effects. Consequently, there has been growing interest in non-pharmacological approaches, particularly acupuncture and auricular therapy, due to their favorable safety profiles and reported efficacy in alleviating migraine symptoms. Auricular therapy, a microsystem of acupuncture applied to specific points on the external ear, has gained popularity for its simplicity, low risk, and therapeutic potential. Despite its increasing clinical use, robust scientific evidence supporting the effectiveness of auricular therapy for migraine remains insufficient, underscoring the need for well-designed clinical studies to validate its therapeutic value.
Eligibility criteria
Qualifiers
Diagnosed as having migraine with aura and without aura according to the diagnostic criteria specified by the ICHD 3;
Aged between 18 and 65 years old;
Provided written informed consent;
Headache lasting for 4 to 72 hours and occur at least 5 times (untreated or poorly treated);
Disqualifiers
All other diagnoses of chronic, tension-type headache, cluster headache and/or secondary headaches;
History of psychotic disorder(s).;
Pregnancy or lactation;
Severe somatic disorder(s);
Trial design
Treatments tested in this trial
- Auricular acupuncture
- Acupuncture